Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126499) titled 'A double-cohort, single-center, open-label clinical study of irinotecan/irinotecan liposomes (II) combined with oxaliplatin and bevacizumab in patients with advanced colorectal cancer who have failed standard second-line treatment' on June 10.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shanghai East Hospital
Condition:
Advanced colorectal cancer
Intervention:
Experimental Group 1:Bevacizumab: 5 mg/kg, intravenous infusion, d1
Irinotecan: 150-180mg/m^2, intravenous infusion, day 1
Oxaliplatin: 85mg/m^2, IV, d1, intravenous infusion for 2-6 hours
Recruitment Status: Not Recru...